KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Goodwill: 2020-2024

Historic Goodwill for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $148.9 million.

  • Recursion Pharmaceuticals' Goodwill rose 211.28% to $162.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.0 million, marking a year-over-year increase of 211.28%. This contributed to the annual value of $148.9 million for FY2024, which is 185.99% up from last year.
  • According to the latest figures from FY2024, Recursion Pharmaceuticals' Goodwill is $148.9 million, which was up 185.99% from $52.1 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Goodwill registered a high of $148.9 million during FY2024, and its lowest value of $801,000 during FY2020.
  • For the 3-year period, Recursion Pharmaceuticals' Goodwill averaged around $67.2 million, with its median value being $52.1 million (2023).
  • Data for Recursion Pharmaceuticals' Goodwill shows a peak YoY surged of 6,398.88% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Recursion Pharmaceuticals' Goodwill stood at $801,000 in 2020, then remained steady at $801,000 in 2021, then remained steady at $801,000 in 2022, then surged by 6,398.88% to $52.1 million in 2023, then soared by 185.99% to $148.9 million in 2024.